- Home
- ANGO vs BME Comparison
ANGO vs BME Comparison
Compare ANGO & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- BME
- Stock Information
- Founded
- ANGO 1988
- BME 2005
- Country
- ANGO United States
- BME United States
- Employees
- ANGO N/A
- BME N/A
- Industry
- ANGO Medical/Dental Instruments
- BME Trusts Except Educational Religious and Charitable
- Sector
- ANGO Health Care
- BME Finance
- Exchange
- ANGO Nasdaq
- BME Nasdaq
- Market Cap
- ANGO 439.5M
- BME 462.3M
- IPO Year
- ANGO 2004
- BME N/A
- Fundamental
- Price
- ANGO $10.12
- BME $35.84
- Analyst Decision
- ANGO Strong Buy
- BME
- Analyst Count
- ANGO 2
- BME 0
- Target Price
- ANGO $14.00
- BME N/A
- AVG Volume (30 Days)
- ANGO 422.1K
- BME 34.0K
- Earning Date
- ANGO 07-15-2025
- BME 01-01-0001
- Dividend Yield
- ANGO N/A
- BME 6.26%
- EPS Growth
- ANGO N/A
- BME N/A
- EPS
- ANGO N/A
- BME 1.44
- Revenue
- ANGO $283,320,000.00
- BME N/A
- Revenue This Year
- ANGO N/A
- BME N/A
- Revenue Next Year
- ANGO $6.35
- BME N/A
- P/E Ratio
- ANGO N/A
- BME $28.37
- Revenue Growth
- ANGO N/A
- BME N/A
- 52 Week Low
- ANGO $5.47
- BME $35.53
- 52 Week High
- ANGO $13.50
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- ANGO 58.79
- BME 46.76
- Support Level
- ANGO $9.78
- BME $35.46
- Resistance Level
- ANGO $10.40
- BME $35.99
- Average True Range (ATR)
- ANGO 0.35
- BME 0.47
- MACD
- ANGO 0.10
- BME 0.04
- Stochastic Oscillator
- ANGO 76.69
- BME 58.71
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.